专家团队
专家简介
  • 李志刚

    职称:主任医师

    中西医结合科主任、主任医师、教授、博士、博士后、博导,海南省拔尖人才。 擅长使用国际先进的肿瘤微创治疗技术,如各种腔镜(胸腔镜、腹腔镜、气管镜、胃镜和肠镜等),各种肿瘤消融技术(氢氦刀冷冻消融、射频消融、微波消融、光动力消融和放射性粒子植入技术)和肿瘤血管介入技术。

  • 预约价格:20元

    李志刚,主任医师,教授、博士、博士后、博导,现任海南省肿瘤医院中西医结合科主任,海南省拔尖人才,毕业于内蒙古医学院;在日本京都大学肿瘤外科硕博连读;在美国休斯敦贝勒医学院读博士后;美国休斯敦安德森癌症中心学习。在内蒙古第二医院工作十年,担任美国休斯敦安德森癌症中心讲师、天津医科大学总医院肿瘤外科教授、博士生导师、天津市肺癌研究所肺癌转移实验室负责人(PI)、天津市中西医结合医院南开医院肿瘤中心主任,2015年至今任海南省肿瘤医院中西医结合科主任。

    李志刚教授拥有十余年的国外留学背景及二十余年的国际临床经历,擅长使用国际先进的肿瘤微创治疗技术,例如各种腔镜(胸腔镜、腹腔镜、气管镜、胃镜和肠镜等),例如各种肿瘤消融技术(氢氦刀冷冻消融、射频消融、微波消融、光动力消融和放射性粒子植入技术)和肿瘤血管介入技术。治疗患者超过七千余例,疗效显著。

    李志刚教授在十多年的外国留学生活中,接受了中西方文化的洗礼,因此促就了他在医学方面想法独具创新、打破传统思维、与时俱进,针对肿瘤患者除了要面对肿瘤局部问题及治疗过程中所出现的全身各脏器功能紊乱的问题,开展了中医药与现代技术相结合的中西医结合肿瘤微创综合治疗,李志刚教授在国外流行的“五师查房”模式基础上加以改善,形成一套具有中国特色的“五师查房”,即西医临床医师、中医师、营养师、疼痛医师和心理医师,五类专科医生常规在患者床旁共同诊治,体现了肿瘤综合治疗的科学性、精准性、时效性、连续性和有效性。


    医疗专长:

    擅长外科治疗。擅长使用国际先进的肿瘤微创治疗技术,例如各种腔镜(胸腔镜、腹腔镜、气管镜、胃镜和肠镜等),例如各种肿瘤消融技术(氢氦刀冷冻消融、射频消融、微波消融、光动力消融和放射性粒子植入技术)和肿瘤血管介入技术。治疗患者超过七千余例,疗效显著。


    科研方向:
    肿瘤发生与转移机制研究
    学术研究

    主持或参与的研究课题

    1、主持国家自然科学基金(NSFC)面上项目。项目名称:雄性激素水平低下诱发前列腺癌的分子机制

    2、指导国家自然科学基金青年课题

    项目名称:DNA甲基化、组蛋白修饰调控非小细胞肺癌lncRNAMALAT1表达的分子机制研究

    3、主持国家中医药管理局全国名老中医药专家传承工作室建设项目

    项目名称:中药核桃青皮活性因子抗食管癌分子机制研究


    学会协会任职

    中国抗癌协会第五届肿瘤转移专业委员会委员

    中国抗癌协会第一届肿瘤热疗专业委员会委员

    海南省抗癌协会肿瘤康养专业委员第一届委员会副主任委员

    国家肿瘤微创治疗产业技术创新战略联盟中西医结合微创治疗专业委员会常务委员

    中国研究型医院学会第一届肝病专业委员会委员

    中国中西医结合学会第三届科研院所工作委员会委员

    北京肿瘤防治研究会缓和医疗分委会委员

    海南省肿瘤防治协会第一届理事会理事

    海南省肿瘤防治协会肿瘤微创专业委员会第一届委员会副主任委员

    海南省免疫学会第三届理事会理事

    海南省免疫学会第三届理事会中医免疫专业委员会副主任委员

    海南省非公立医疗机构协会介入专业委员会第一届委员会常务委员


    个人荣誉

    1、2005年10月获得美国国防部医学研究基金

    2、Department of Defense(DOD)FiscalYear2005(FY05)

    3、Prostate Cancer Research Program(PCRP).

    4、Funding Number:PC05-POSTDOC(PC050182)


    论文著作

    1、Ze-Han Liu, Qi Zhang, Yi-Jie Ding, Ying-Hui Ren, Hui-Peng Yang, Qing Xi, Ying-Nan Cheng, Guo-Lin Miao, Hong-Kun Liu, Cai-Xia Li, Wen-Qiang Yan, Yan Li, Zhenyi Xue, Li-juan Zhang, Xin-Ye Li, Chen-Long Zhao, Yurong Da, Xian-Zhong Wu, Jun-Qiang Chen, Rongxin Zhang, Zhi-Gang Li(李志刚,通讯),Overexpression of CHD1L is Associated with Poor Survival and Aggressive Tumor Biology in Esophageal Carcinoma. Oncotarget. 2017 Jun 29. doi: 10.18632/oncotarget.18830 (IF: 5.168).  

    2、Guo F, Jiao F, Song Z, Li S, Liu B, Yang H, Zhou Q, Li Z(李志刚,通讯 Regulation of MALAT1 expression by TDP43 controls the migration and invasion of non-small cell lung cancer cells in vitro. Biochem Biophys Res Commun, 2015, Sept  465(2):293-298. (IF2.371Cited:3).

    3、Guo F, Guo L, Li Y, Zhou Q, Li Z(李志刚,通讯MALAT1 is an oncogenic long non-coding RNA associated with tumor invasion in non-small cell lung cancer regulated by DNA methylation. Int J Clin Exp Pathol, 2015, Dec 8(12):15903-15910. (IF1.581Cited:2).

    4、Yan S, Tian S, Kang Q, Xia Y, Li C, Chen Q, Zhang S, Li Z(李志刚,通讯)Rhizoma Paridis Saponins Suppresses Tumor Growth in a Rat Model of N-Nitrosomethylbenzylamine-Induced Esophageal Cancer by Inhibiting Cyclooxygenases-2 Pathway. PLoS One. 2015 Jul 6;10(7): IF3.75cited:0).

    5、Wang DB1, Lu XK, Zhang X, Li ZG(李志刚), Li CX. Carbonic anhydrase 1 is a promising biomarker for early detection of non-small cell lung cancer. Tumour Biol. 2015 Aug 1. IF3.6 cited:2).

    6、Li S, Li Z(李志刚,并列)Guo F, Qin X, Liu B, Lei Z, Song Z, Sun L, Zhang HT, You J, Zhou Q. miR-223 regulates migration and invasion by targeting Artemin in human esophageal carcinoma. J Biomed Sci. 2011 Mar 31;18:24IF2.4 cited:77).

    7、Wan X, Li ZG(李志刚) Yingling JM, Yang J, Starbuck MW, Ravoori MK, Kundra V, Vazquez E, Navone NM. Effect of transforming growth factor beta (TGF-β) receptor I kinase inhibitor on prostate cancer bone growth. Bone. 2012 Mar;50(3):695-703. IF4.09, cited:29 ).

    8、Mohamedali KA, Li ZG(李志刚), Starbuck MW, Wan X, Yang J, Kim S, Zhang W, Rosenblum MG, Navone NM.Inhibition of prostate cancer osteoblastic progression with VEGF121/rGel, a single agent targeting osteoblasts, osteoclasts, and tumor neovasculature. Clin Cancer Res. 2011 Apr 15;17(8):2328-38. Epub 2011 Feb 22.IF6.5 , cited:22).

    9、Li ZG(李志刚), Mathew P, Yang J, Starbuck MW, Zurita AJ, Liu J, Sikes C, Multani AS, Efstathiou E, Lopez A, Wang J, Fanning TV, Prieto VG, Kundra V, Vazquez ES, Troncoso P, Raymond AK, Logothetis CJ, Lin SH, Maity S, Navone NM. Androgen receptor-negative human prostate cancer cells induce osteogenesis in mice through FGF9-mediated mechanisms. J Clin Invest. 2008 Aug;118(8):2697-710.IF16.915 , cited:104).

    10、Li ZG(李志刚), J Yang, ES Vazquez, D Rose, F Vakar-Lopez, P Mathew, A Lopez, CJ Logothetis, S-H Lin and NM Navone. Low-density lipoprotein receptor-related protein 5 (LRP5) mediates the prostate cancer-induced formation of new bone. Oncogene. 2008 Jan 24;27(5):596-60 (IF: 6.872 cited:53).

    11、Li ZG(李志刚), Heidi Y Shi and Ming Zhang. Targeted expression of maspin in tumor vasculatures induces endothelial cell apoptosis. Oncogene. 2005 Mar 17;24(12):2008-19 (IF:6.872, cited:132).

    12、Li ZG(李志刚), Hong T, Shimada Y, Komoto I, Kawabe A, Ding Y, Kaganoi J, Hashimoto Y, Imamura M. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis. 2002 Sep;23(9):1531-6 (IF: 5.406 , cited:260 ).

    13、Li ZG(李志刚), Shimada Y, Kawabe A, Sato F, Maeda M, Komoto I, Hong T, Ding Y, Kaganoi J, Imamura M. Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by JTE-522, a selective COX-2 inhibitor. Carcinogenesis. 2001 Apr;22(4):547-51. (IF:5.406 , cited:238).

    14、Li ZG(李志刚),  Schem C, Shi YH, Medina D, Zhang M. Increased COX2 expression enhances tumor-induced osteoclastic lesions in breast cancer bone metastasis. Clin Exp Metastasis.  2008; 25(4):389-400. (IF: 2.514, cited:114).

    15、Li ZG(李志刚), Shimada Y, Uchida S, Maeda M, Kawabe A, Mori A, Itami A, Kano M, Watanabe G, Imamura M. TGF-alpha as well as VEGF, PD-ECGF and bFGF contribute to angiogenesis of esophageal squamous cell carcinoma. Int J Oncol. 2000 Sep;17(3):453-60. (IF:2.931, cited:92) .

    16、Li ZG(李志刚), Shimada Y, Sato F, Maeda M, Itami A, Kaganoi J, Komoto I, Kawabe A, Imamura M. Inhibitory effects of epigallocatechin-3-gallate on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in F344 rats. Int J Oncol. 2002 Dec; 21(6):1275-83 (IF: 2.931, cited:79).

    17、Li ZG(李志刚), Shimada Y, Sato F, Maeda M, Itami A, Kaganoi J, Komoto I, Kawabe A, Imamura M. Promotion effects of hot water on N-nitrosomethylbenzylamine-induced esophageal tumorigenesis in F344 rats. Oncol Rep. 2003 Mar-Apr;10(2):421-6 (IF: 1.597, cited:88).

    18、Nagatani S, Shimada Y, Li ZG(李志刚), Kaganoi J, Kan T, Maeda M, Watanabe G, Imamura M. Validation of intra-operative detection of paratracheal lymph node metastasis using real-time RT-PCR targeting esophageal squamous cell carcinoma. Jpn J Clin Oncol. 2003 Nov;33(11):549-55. (IF:0.967).

    19、Shimada Y, Sato F, Maeda M, Watanabe G, Nagatani S, Kaganoi J, Hashimoto Y, Kan T, Li ZG(李志刚), Imamura M. Validity of intraoperative pathological diagnosis of paratracheal lymph node as a strategy for selection of patients for cervical lymph node dissection during esophagectomy. Dis Esophagus. 2003;16(3):246-51.(IF:0.797).

    20、Ding Y, Shimada Y, Gorrin-Rivas MJ, Itami A, Li ZG(李志刚), Hong T, Maeda M, Komoto I, Kawabe A, Kaganoi J, Imamura M. Clinicopathological significance of human macrophage metalloelastase expression in esophageal squamous cell carcinoma. Oncology. 2002; 63(4):378-84 (IF:2.114).

    21、Shimada Y, Imamura M, Sato F, Maeda M, Kaganoi J, Hashimoto Y, Kan T, Nagatani S, Li ZG(李志刚). Indications for abdominal para-aortic lymph node dissection in patients with esophageal squamous cell carcinoma. Surgery. 2002 Jul;132(1):93-9.(IF:2.355).

    22、Sato F, Shimada Y, Li ZG(李志刚), Kano M, Watanabe G, Maeda M, Kawabe A, Kaganoi J, Itami A, Nagatani S, Imamura M. Paratracheal lymph node metastasis is associated with cervical lymph node metastasis in patients with thoracic esophageal squamous cell carcinoma. Ann Surg Oncol. 2002, Jan-Feb;9(1):65-70.(IF:4.035).

    23、Hong T, Shimada Y, Uchida S, Itami A, Li ZG(李志刚), Ding Y, Kaganoi J, Komoto I, Sakurai T, Imamura M.Expression of angiogenic factors and apoptotic factors in leiomyosarcoma and leiomyoma. Int J Mol Med. 2001 Aug; 8(2):141-8.(IF:3.190).

    24、sato F, Shimada Y, Li ZG(李志刚), Watanabe G, Maeda M, Imamura M. Lymph node micrometastasis and prognosis in patients with oesophageal squamous cell carcinoma. Br J Surg. 2001 Mar;88(3):426-32. (IF3.580).

    25、Ding Y, Shimada Y, Kano M, Itami A, Kawabe A, Maeda M, Li ZG(李志刚), Hong T, Sato F, Kaganoi J, Imamura M. PTEN/MMAC1 expression in esophageal squamous cell carcinomas. Int J Oncol. 2000, Oct;17(4):695-9. (IF:2.295).

    26、Kano M, Shimada Y, Kaganoi J, Sakurai T, Li ZG(李志刚), Sato F, Watanabe G, Imamura M. Detection of lymph node metastasis of oesophageal cancer by RT-nested PCR for SCC antigen gene mRNA, Br J Cancer. 2000 Jan;82(2):429-35. (IF:3.580).

    27、Uchida S, Shimada Y, Watanabe G, Li ZG(李志刚), Hong T, Miyake M, Imamura M.Motility-related protein (MRP-1/CD9) and KAI1/CD82 expression inversely correlate with lymph node metastasis in oesophageal squamous cell carcinoma, Br J Cancer. 1999 Mar; 79 (7-8):1168-73. (IF:3.742).